澳大利亚的痴呆症:诊断后的临床建议
David Foxe1,2, Mirelle D'Mello1,2, Sau Chi Cheung1,2,3
1School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.
Australasian journal on ageing
|February 26, 2024
概括
接受痴呆症诊断需要敏感的沟通和全面的支持. 在诊断后解决关键话题可以改善整个痴呆过程中的患者和家庭福祉.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 公共卫生 公共卫生
背景情况:
- 痴呆症诊断和随后的支持对患者和家人产生重大影响.
- 当前的重点往往优先考虑评估,而不是提供信息和支持.
- 有效的沟通对于患者和家庭的调整至关重要.
研究的目的:
- 强调在痴呆症护理中诊断对话和信息传递的重要性.
- 概述在痴呆症诊断后应讨论的关键话题.
- 通过全面的支持,改善整体痴呆症护理过程.
主要方法:
- 关于痴呆症诊断沟通最佳实践的文献综述.
- 对诊断后支持主题的专家建议的综合.
- 为以患者为中心的痴呆症护理讨论制定框架.
主要成果:
- 诊断对话需要敏感,清晰,并根据个体需求量身定制.
- 高质量,可访问的信息是诊断后至关重要的.
- 讨论的十个关键领域包括干预,组织支持,法律/财务问题,驾驶和护理人员资源.
结论:
- 对诊断后讨论的结构化方法可以增强痴呆症疾病的管理.
- 整体地解决这些问题可以改善患者,护理人员和家庭的体验.
- 优先考虑敏感的沟通和全面的支持对于痴呆症护理至关重要.
相关概念视频
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Cognitive Development During Adulthood
109
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
109
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546


